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Abst ract  
The interaction of the anti-cancer drug cis-diamminedichloroplatinum(II) (cisPt) with model membranes was studied, with emphasis 
on the cisPt and phospholipid species involved. Binding studies using large unilamellar vesicles have revealed that: (i) Interaction 
involved negatively charged phospholipids only, and (ii) Interaction with negatively charged phospholipids was observed only in buffers 
with low CI-  concentration, i dicating that aquated, positively charged cisPt is involved. Binding to all negatively charged phospholipids 
tested was highest at pH 6.0. At pH 7.4 a high and specific binding was observed with phosphatidic acid and phosphatidylserine. The 
consequences of cisPt binding on the organization of lipids was investigated with differential scanning calorimetry studies. These studies 
have indicated a higher ordering of dispersions of negatively charged phospholipids in the presence of divalent cationic cisPt. 
Summarizing, the interaction of positively charged cisPt species with negatively charged phospholipids i significant and should be 
considered in in vivo experiments. 
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1. Introduction 
Abbreviations: Buffer A, 10 mM Pipes, 100 mM NaCI, 1 mM EGTA, 
pH 7.4; Buffer B, 10 mM Pipes, 50 mM Na2SO 4, I mM EGTA, pH 7.4; 
Buffer C, 10 mM Mes, 100 mM NaC1, 1 mM EGTA, pH 6.0; Buffer D, 
10 mM Mes, 50 mM Na2SO4, 1 mM EGTA, pH 6.0; cisPt, cis-diam- 
minedichloroplatinum(II) and its aquated products; CL, cardiolipin from 
bovine heart; DOPA, 1,2-dioleoyl-sn-glycero-3-phosphatidic acid; DOPC, 
1,2-dioleoyl-sn-glycero-3-phosphocholine; DOPE, 1,2-dioleoyl-sn- 
glycero-3-phosphoethanolamine; DOPG, 1,2-dioleoyl-sn-glycero-3-phos- 
phoglycerol; DOPS, 1,2-dioleoyl-sn-glycero-3-phosphoserine; DMPG,
1,2-dimyristoyl-sn-glycero-3-phosphoglycerol; DPPC, 1,2-dipalmitoyl- 
sn-glycero-3-phosphocholine; DPPG, 1,2-dipalmitoyl-sn-glycero-3-phos- 
phoglycerol; DSC, differential scanning calorimetry; EGTA, ethylenegly- 
col bis(13-aminoethyl ether)-N,N,N',N'-tetraacetic acid; LUVET, large 
unilamellar vesicles prepared by extrusion; Mes, 2-morpholinoethane- 
sulfonic acid; NFAAS, non flame atomic absorption spectroscopy; PI, 
phosphatidylinositol fr m soybean; Pipes, piperazine-1,4-diethanesulfonic 
acid; Pt, platinum; SM, sphingomyelin from egg. 
* Corresponding author. Fax: + 31 30 2522478. 
t Present address: ATO-DLO, P.O. Box 17, 6700 AA Wageningen, 
The Netherlands. 
The anti-cancer drug cis-diamminedichloroplatinum(II) 
(cisPt) has an established role in the treatment of testicular, 
ovarian, bladder, small cell lung as well as head and neck 
cancer [1]. The reactive species of the drug is not the 
native cisPt, but aquated cisPt. If cis-diamminedichloro- 
platinum(II) is dissolved in water, the chloride atoms are 
subsequently replaced by water molecules in a stepwise 
manner, resulting in mono- and diaquated cisPt [2]. The 
extent of this aquation is determined by reaction time and 
the concentration of C1- present in the buffer. With a H20 
molecule replacing a CI- ion, cisPt becomes a positively 
charged, weak acid. Depending on the pH of the buffer, 
aquated cisPt contains a net charge of 0, + 1, or + 2 [1] 
(Fig. 1A). Aquation of cisPt in vivo is thought o occur in 
the cytosol, since the pH and C1- concentration are lower 
than that of the blood plasma. The positively charged 
aquated cisPt species are very reactive towards everal cell 
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Fig. 1. Equilibrium distribution of the several cisPt species in different 
buffers. Plotted are uncharged, monovalent and divalent cationic species. 
(A) Structure of the mononuclear species. Uncharged species are unreac- 
tire. Monovalent cations and the divalent cationic species are most 
reactive. (B) Distribution of 150 I~M total cisPt, a concentration represen- 
tative for the binding experiments. (C) Distribution of 5 mM total cisPt, 
used in the DSC experiments. Black bars represent distribution i buffer 
A, arched bars represent distribution i buffer B, dotted bars represent the 
distribution i buffer C, and white bars represent distribution of cisPt in 
buffer D. Buffer composition is described inSection 2. Distribution of the 
species i  calculated using the given concentration f CI- and total cisPt 
and an equilibrium constant K of 1.78.10 -3 for the first aquation step, 
PtCI2(NH3) 2~ PtCI(H2OXNH3) ~- +CI- and 2.75.10 -4 for the second 
aquation step, PtCI(H20)(NH3) ~" ~ Pt(H20)2(NH3 )2+ +C1-. Subse- 
quently, for the monoaquated cisplatin the distribution between eutral 
and 1 + species was calculated using the pH value and a pK, of 6.41. 
The distribution between eutral, 1+, and 2+ for the diaquated cisplatin 
species was calculated using the pH value and pK, values of 7.21 and 
5.37 [13,14]. 
components. Much attention has been paid to the interac- 
tion of cisPt with DNA and -SH groups of proteins and 
peptides [1,3,4]. However, little is known about c isPt-  
membrane interactions and virtually nothing has been re- 
ported about cisPt-phosphol ipid interactions, although 
these interactions may play an important role in the cyto- 
toxic mechanism of cisPt. For other drugs, interactions 
with membranes or phospholipids have important conse- 
quences for their cytotoxicity, side-effects and transport 
across the plasma membrane. For instance, doxorubicin 
interaction with phosphoinositides and phosphatidylserine 
can have an effect on signal transduction [5,6], and its 
cardiotoxic side-effect is attributed to its interaction with 
cardiolipin [7]. Aminoglucosides interact with phospho- 
inositides and this has been associated with nephrotoxicity 
[8], one of the severe side-effects also observed with cisPt. 
Furthermore, cisPt-membrane binding studies may help to 
interpret he results of cisPt influx experiments, of which 
the mechanism has not yet been resolved [9]. 
This paper describes the interaction of cisPt with phos- 
pholipids. Special attention was paid to the nature of the 
platinum species involved, i.e. aquated, positively charged, 
or neutral, by manipulating the buffers in which the experi- 
ments were performed, and to the phospholipid species 
involved. 
Part of these results have been presented on the 7 th 
ISPCC, 1995, Amsterdam, The Netherlands (abstract No. 
103). 
2. Materials and methods 
2.1. Materials 
cisPt was purchased from Sigma (St. Louis, MO, USA). 
All l ipids, except 1,2-dipalmitoyl-sn-glycero-3-phos- 
phocholine (DPPC) and 1,2-dipalmitoyl-sn-glycero-3- 
phosphoglycerol (DPPG), were obtained from Avanti Polar 
Lipids (Birmingham, AL, USA). DPPC was prepared in 
this lab as described [10]. DPPG was prepared from DPPC 
using phospholipase D mediated base exchange [11]. 
2.2. Preparation of cis-diamminedichloroplatinum(lI) stock 
solutions and buffers employed 
cisPt was dissolved in buffer to a final concentration of 
5 mM. The solution was incubated for 1 h at 37-40°C and 
vortexed occasionally to dissolve the cisPt completely. The 
buffers in which the stock solution was prepared were of 
the following composition: 
10 mM Pipes, 100 mM NaC1, 1 mM EGTA, pH 7.4 
(Buffer A) 
10 mM Pipes, 50 mM Na2SO4, 1 mM EGTA, pH 7.4 
(Buffer B) 
10 mM Mes, 100 mM NaCI, 1 mM EGTA, pH 6.0 
(Buffer C) 
10 mM Mes, 50 mM Na:SO 4, 1 mM EGTA, pH 6.0 
(Buffer D). 
Unless stated otherwise these stock solutions were used 
within 2 h ( ' freshly prepared'). In order to allow for the 
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aquation of cisPt to approach equilibrium most experi- 
ments involved incubation periods of 3 days. Alternatively, 
stock solutions of cisPt were allowed to aquate for 3 days 
in the dark at room temperature ('pre-incubated cisPt'). 
2.3. Preparation of model membranes 
ature in the dark, and centrifuged for 20 min at 14000 X g 
at room temperature. The pellet was transferred to a 20 ill 
sample pan and immediately scanned 5 times. Heating and 
cooling scans were determined at a rate of 5 K/min in the 
range from 20 to 55°C against an empty sample pan as 
reference. 
Large unilamellar vesicles (LUVET) employed in the 
binding experiments were prepared in buffer A, B, C, or D 
by extrusion through polycarbonate filters with 400-nm 
pores (Costar-Nuclepore Europe, Badhoevedorp, The 
Netherlands) as described previously [6]. LUVET were 
composed of pure phospholipids, except for DOPE. In that 
case a 1:1 mixture with DOPC was used to prevent he 
formation of non-bilayer structures. 
Multilamellar vesicles (MLV) used for differential scan- 
ning calorimetry (DSC) measurements were prepared by 
hydration of the dried lipid-films in Buffer A, B, C or D in 
the absence or presence of 5 mM freshly prepared cisPt. 
The samples were freeze-thawed and vortexed 10 times 
and transferred to Eppendorf tubes and used for DSC 
experiments. 
2.6. Platinum determination 
Samples containing Pt were thawed and diluted in water 
immediately before Pt determination such that the concen- 
tration was approximately 0.4 p~M. The concentration of Pt 
was determined with a non-flame atomic absorption spec- 
trophotometer, type AAS 4000 Perkin Elmer using a plat- 
inum lamp and a deuterium lamp for background correc- 
tion. For the calibration curve a solution of known concen- 
trations of K2PtC16 was used. 
2.7. Other methods 
The phospholipid concentration was determined accord- 
ing to Rouser [12]. 
2.4. Binding assay 
Binding of cisPt to model membranes was assayed as 
described by [6] with the following modifications: 250 Ixl 
of membrane suspensions (20 mM lipid-P i) were mixed 
with 750 I~1 cisPt solution in buffer A, B, C, or D in the 
range of 25 to 250 txM cisPt (final concentrations). Dupli- 
cate samples were incubated in the dark at room tempera- 
ture for 3 days and freeze-thawed two times immediately 
after addition of cisPt and two times at the end of the 
incubation period. Freeze-thaw steps were performed to 
allow equilibration between the internal and external vol- 
ume and, since passive diffusion of cisPt across phospho- 
lipid bilayers is very slow (Speelmans, G., unpublished 
data), to allow binding of cisPt to lipids present in the 
inner leaflet of the bilayer. The model membranes and 
bound drug were pelleted (45 min at 436 000 X g and 20°C 
in a Beckman TLA 100.2 rotor). The top 800 pA were 
collected for determination of free Pt. The amount of 
lipid-P~ was determined in the supernatant fraction (negli- 
gible) and pellet fraction. Blanks without lipid were used 
to determine the total amount of drug. Corrections were 
made for binding of cisPt to tubes (which was low). 
Samples of which the platinum (Pt) concentration had to 
be determined were stored at - 20°C prior to Pt determina- 
tion. 
2.5. Differential scanning calorimetry 
3. Results 
3.1. Conditions 
Since it is of primary interest o distinguish between the 
different cisPt species with respect o their interaction with 
phospholipids, different buffers were employed to manipu- 
late the distribution of cisPt species. Buffers contained 100 
mM C1- (Buffer A and C), or no C1- (Buffer B and D) 
and had a pH value of 7.4 (Buffer A and B), or pH 6.0 
(Buffer C and D). As C1- is slowly released upon aquation 
of cisPt the initial concentration of cisPt present also 
influences the extend of aquation in buffer B and D. 
In Fig. 1 the distribution of the calculated ifferently 
charged cisPt species in buffer A, B, C, and D, is shown 
based on pK a values and equation rate constants given in 
the literature [ 13,14]. Results are shown for a cisPt concen- 
tration of 150 IxM (Fig. 1B) which is a concentration 
representative for the binding experiments, and 5 mM (Fig. 
1C) which was employed in the DSC experiments. The 
concentration of positively charged cisPt is highest in 
buffers without C1- and higher at pH 6.0 than at pH 7.4. 
Since the aquation of cisPt is a rather slow process, with a 
half time of several hours [15], stock solutions were either 
preincubated for 3 days or incubations were performed 
during 3 days in order to allow for the equilibrium to be 
approached. 
Differential scanning calorimetry (DSC) experiments 
were performed with DPPC and DPPG lipids in a Perkin 
Elmer DSC-2 apparatus calibrated with Indium. Multil- 
amellar vesicles were incubated for 3 days at room temper- 
3.2. Binding of cisPt to phospholipid vesicles 
Phospholipids were added as large unilamellar vesicles 
(LUVET) and in order to allow cisPt to react with both 
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sides of the membrane, freeze-thaw steps were applied. No 
large differences were observed if Pt binding was calcu- 
lated from the data of the cisPt concentration i  the 
supernatants, or directly, when determined in the pellet 
fraction (containing the phospholipids). 
In Fig. 2 the results of the binding experiments are 
shown. The following phospholipid specificity can be ob- 
served for binding: Binding is low or negligible to the 
overall neutral lipids phosphatidylcholine (PC), sphingo- 
myelin (SM) and phosphatidylethanolamine (PE), whereas 
significant binding is observed to all negatively charged 
lipids tested; phosphatidic acid (PA), phosphatidylglycerol 
(PG), phosphatidylserine (PS), phosphatidylinositol (PI) 
and cardiolipin (CL). Clear differences in binding can be 
observed ependent on the buffer employed. Binding of 
cisPt to negatively charged phospholipids i  high in buffers 
without CI- (Fig. 2B,D), whereas hardly any binding is 
observed in the presence of 100 mM C1- (Fig. 2A,C), 
except for DOPA at pH 7.4 (Fig. 2A). When buffers 
without CI- are compared, it appears that binding is 
higher at pH 6.0 (Fig. 2D) than at pH 7.4 (Fig. 2B). At pH 
6.0 binding to all negatively charged phospholipids is 
comparably high, but at pH 7.4 a strong binding is ob- 
served to PA and PS, whereas binding to CL, PG, and PI is 
much lower. No apparent binding affinities can be calcu- 
lated since the binding curves indicate that saturation does 
not occur at the cisPt concentrations employed. In order to 
directly compare binding of cisPt to different phospho- 
lipids in different buffers, the amount of bound cisPt per 
phospholipid (mmol/mol ipid-P i) at a concentration of 
100 p,M free cisPt is given in Table 1. 
Binding of cisPt to phospholipids i highest in buffer 
with the highest concentration of positively charged cisPt 
species (Fig. 1), and high for all negatively charged phos- 
pholipids tested, but negligible for all zwitterionic phos- 
pholipids tested, indicating the involvement of an electro- 
static drug-phospholipid interaction. 
3.3. Differential scanning calorimetry measurements 
With differential scanning calorimetry (DSC) the conse- 
quences of the interactions of compounds for the phase 
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Fig. 2. Binding of cisPt to large unilamellar vesicles composed ofvarious phospholipids in buffers of various composition. Binding experiments were 
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behavior of phospholipids can be studied. The transition 
temperature and/or enthalpy of the gel to liquid crystalline 
phase transition of phospholipids can change in the pres- 
ence of drug molecules and this can give information 
about the type of interaction. Therefore, it was studied 
whether the presence of cisPt changed the transition tem- 
perature of negatively charged phospholipids (DPPG) in 
buffer containing a high concentration of C1- (Buffer A, 
C) or no C1- (Buffer B, D). The interaction with DPPG 
was compared to the interaction with the zwitterionic 
phospholipid DPPC. In Fig. 3A heating scans of DPPG are 
shown, performed in the absence or presence of 5 mM 
cisPt after 3 days incubation at room temperature in buffer 
A or D. When experiments are performed in buffer A (pH 
7.4, 100 mM C1-) no difference between scans in the 
absence (scan a) or presence (scan b) of cisPt is observed, 
with the temperature of the gel to liquid-crystalline phase 
transition at 41.6°C in both cases. The same phenomenon 
is observed in buffer C (data not shown). However, in 
buffer B (pH 7.4, without C1 ) a small peak broadening 
and an increase in the transition temperature were ob- 
served in the presence of cisPt (data not shown). This 
effect appears most pronounced in buffer D (pH 6.0, 
without CI-). Scan d shows a large broadening and dou- 
bling of the peak. Compared to scan c (performed in the 
absence of cisPt) the transition temperature is shifted from 
41.1 (scan c) to 43.8 and 47.2°C (scan d). This shift to 
higher transition temperatures is also observed in cooling 
scans of DPPG with cisPt and was already visible to some 
extent after 1 day incubation and maximal after 3 days 
incubation because of the slow aquation of native cisPt 
(data not shown). In addition, the transition enthalpy (AH) 
of DPPG is increased from 8.7 in the absence of cisPt to 
10.1 kcal/mol in the presence of cisPt. In Fig. 3B the 
results are shown with the zwitterionic phospholipid DPPC. 
In buffer A (scan a, b) as well as in buffer D (scan c, d) 
the presence of cisPt (scan b, d) has no effect on the 
pretransition and main transition temperature of DPPC (of 
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Fig. 3. Differential scanning calorimetry of phospholipids in the presence 
or absence of cisPt. (A) Heating scans of DPPG in buffer pH 7.4 with 
100 mM El- (scan a, b) or in buffer pH 6.0 without CI- (scan c, d) in 
the absence of cisPt (scan a, c) or in the presence of 5 mM cisPt (scan b, 
d). (B) Heating scans of DPPC in buffer pH 7.4 with 100 mM CI- (scan 
a, b) or in buffer pH 6.0 without C1- (scan c, d) in the absence of cisPt 
(scan a, c) or in the presence of 5 mM cisPt (scan b, d). 
Table 1 
Amount of mmol cisPt bound per mol phospholipid-P i 
concentration f 100 IzM 
at a free cisPt 
Phospholipid Buffer A a Buffer B Buffer C Buffer D 
DOPC < 1 < 1 < 1 2.7 
DOPE/PC < 1 < 1 < 1 1.6 
SM n.d. b < 1 n.d. < 1 
DOPA 5.6 18.5 < 1 61.9 
DOPG < 1 1.5 < 1 50.9 
CL n.d. 3.0 n.d. 14.5 
DOPS < 1 22.8 < 1 42.9 
PI n.d. 2.1 n.d. 29.8 
a Buffer A: 10 mM Pipes, 100 mM NaCI, 1 mM EGTA, pH 7.4; Buffer 
B: 10 mM Pipes, 50 mM Na2SO4, 1 mM EGTA, pH 7.4; Buffer C: 10 
mM Mes, 100 mM NaCI, 1 mM EGTA, pH 6.0; Buffer D: 10 mM Mes, 
50 mM Na2SO4, 1 mM EGTA, pH 6.0. 
b n.d., not determined. 
37.0 and 42.5°C, respectively). This again indicates that 
the binding of cisPt is specific for negatively charged 
phospholipids. 
4. D iscuss ion  
The results presented above describe for the first time 
the interaction of the anti-tumor drug cisPt with phospho- 
lipids. Binding studies and DSC experiments did reveal 
that (i) interaction occurs with all negatively charged 
phospholipids tested, but with none of the zwitterionic 
phospholipids tested, and (ii) interaction occurs mainly in 
buffers without Cl-, and most strongly at low pH. These 
are strong indications that electrostatic interactions are 
involved in cisPt-phospholipid binding. In buffer with lO0 
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mM Cl-, pH 7.4 some binding to phosphatidic acid (PA) 
was observed. PA can have two negative charges at high 
pH and also its small head group, resulting in a high 
charge density, may account for binding under conditions 
where the amount of positively charged cisPt is low. In 
buffer of high pH without CI- the two phospholipids with 
a second ionizable group (PS and PA) show a significant 
higher binding than the other negatively charged phospho- 
lipids. Interestingly, this specific higher binding to PS and 
PA at higher pH values has also been observed for divalent 
cations, such as Mg 2+ [16]. At pH 6.0 in the absence of 
C1 on the other hand, binding to the various negatively 
charged phospholipids is more comparable, although a 
decreased binding affinity has been observed: CL < PS, 
PG, PA. If it is assumed that only mono- and divalent 
charged cisPt species interact with negatively charged 
phospholipids, than the amount of cisPt bound to the 
negatively charged phospholipids in buffer D is in the 
same order as the amount of positively charged cisPt 
present in this buffer under equilibrium conditions. The 
amount of cisPt bound to PA and PS at pH 7.4 in the 
absence of C1 (buffer B) is twice as high as expected 
from the amount of positively charged cisPt present under 
equilibrium conditions in buffer B alone. This indicates 
that upon interaction of cisPt with the phospholipids a shift 
in equilibrium might take place, upon which more posi- 
tively charged cisPt is formed, or that other interactions 
also play a role for these lipids. For PS this indeed seems 
to be the case (Speelmans et al. 1996, unpublished ata). 
A broadening, doubling and increase of the transition 
temperature of negatively charged DPPG was observed in 
the presence of cisPt at low pH and low CI- concentra- 
tion. This effect was not observed for the zwitterionic 
phospholipid DPPC. An increased transition temperature 
indicates a less fluid membrane, which can be explained 
by neutralization of the negatively charged phospholipids 
by positively charged cisPt. This rigidifying effect by 
charge neutralization of negatively charged phospholipids 
has also been observed by increasing the concentration of
H +, Na + or K + [17] and especially by increasing the 
concentration f divalent cations, such as Ca 2+ and Mg 2+ 
[17-19]. The appearance of two transition peaks in the 
DSC scan is perhaps due to the presence of both mono- 
and divalent cationic species of cisPt. An increase of the 
transition temperature of DMPG by 2 K was observed if 
Ca 2+ or Mg 2+ is present in a ratio of 0.06-0.07 mol/mol 
phospholipid [19]. This is in the same order as the ratio 
total (charged and uncharged) cisPt/mol phospholipid. A
possible explanation is that the hydrolysis equilibria of the 
cisPt species change upon binding to negatively charged 
phospholipids and that significantly more positively 
charged cisPt is formed in the presence of negatively 
charged phospholipids than in buffers alone. 
The comparable interaction of cisPt and divalent cations 
with membranes i of great interest and may have impor- 
tant physiological implications. Simpkins [20] observed a
decrease in the number of Ca 2+ binding sites on biological 
membranes, in the presence of cisPt, which may be the 
result of the same phenomenon asobserved by us in model 
membranes, namely charge-charge interaction between 
cisPt and phospholipids. 
Changes in intracellular cisPt concentrations or distribu- 
tion, achieved by (i) interaction with amino acids of pep- 
tides and proteins and (ii) by active effiux, have consider- 
able implications for antitumor activity [21,22]. If redistri- 
bution and competition for binding with DNA might also 
be achieved by binding to negatively charged phospho- 
lipids, this may have important implications for the antitu- 
mor activity of cisPt and related derivative compounds. 
Binding studies at in vivo pH and [C1-] and in the 
presence of proteins and DNA are necessary to ascertain 
the importance of cisPt-phospholipid nteraction. In gen- 
eral the intracellular [CI-] is about 4 raM, whereas this is 
100 mM in the blood plasma. The internal pH in tumor 
cells is lower than the pH of 7.4 of the blood plasma [23]. 
Negatively charged phospholipids play crucial roles in 
signal transduction, oxidative phosphorylation, and cell 
proliferation [7,24,25]. Therefore, cisPt-phospholipid n- 
teraction may have important consequences for these pro- 
cesses. Especially the strong interaction with PS, located in 
the inner leaflet of the plasma membrane, is of interest and 
is currently under investigation. 
In summary, we have shown that the interaction of cisPt 
and its metabolites with phospholipids can be significant 
and should be considered when studying transport and 
binding studies of cisPt and other compounds in vivo. 
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